Showing results (691-700 of 3,789) with videos related to

Sort By:
Pageof 379
Oncoimmunology|November 1, 2018
PD-L1 blockade enhances anti-tumor efficacy of NK cellsJeremiah L Oyer, Sarah B Gitto, Deborah A Altomare, et al.
Oncoimmunology|November 1, 2018
Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patientsEliza Kwiatkowska-Borowczyk, Patrycja Czerwińska, Jacek Mackiewicz, et al.
Oncoimmunology|April 16, 2014
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanomaDevin B Lowe, Anamika Bose, Jennifer L Taylor, et al.
Oncoimmunology|April 19, 2014
Modulating antigen processing for cancer immunotherapyEfstratios Stratikos
Oncoimmunology|April 5, 2014
A novel pathway links telomeres to NK-cell activity: Implications for immunotherapyJulien Cherfils-Vicini, Pasquale Zizza, Eric Gilson, et al.
Oncoimmunology|April 5, 2014
Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancerLinda C Sandin, Thomas H Tötterman, Sara M Mangsbo
Oncoimmunology|April 9, 2014
Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancerPanagiotis Balermpas, Franz Rödel, Christian Weiss, et al.
Oncoimmunology|March 22, 2014
Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapyFlorian Wimmers, Erik Hjg Aarntzen, Gerty Schreibelt, et al.
Oncoimmunology|February 10, 2017
Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based studyYu Wang, Xiang-Yu Zhao, Lan-Ping Xu, et al.
Oncoimmunology|October 21, 2016
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanomaHiroyuki Inoue, Jae-Hyun Park, Kazuma Kiyotani, et al.
Pageof 379